Funding for this research was provided by:
Palatin Technologies, Inc.
Received: 7 April 2021
Accepted: 25 August 2021
First Online: 24 September 2021
: The study was conducted in accordance with Good Clinical Practice requirements, as described in guidelines of the International Conference on Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) and in the Declaration of Helsinki. Each study site was reviewed by a central or local institutional review board or ethics committee. Before any study procedures were initiated, written informed consent was obtained from each subject.
: Not applicable.
: LRD has received research support or consulting fees from AMAG Pharmaceuticals, Inc., and Palatin Technologies, Inc. DAR has received research support and consulting fees from AMAG Pharmaceuticals, Inc., Viveve Medical, and Palatin Technologies, Inc. RCR has received financial or material support from Bayer Healthcare and Eli Lilly, and has received research support and consulting fees from Palatin Technologies, Inc., Shionogi, and Sprout Pharmaceuticals. RJ, JL, and CS are employees and stockholders of Palatin Technologies, Inc.